Registry of the International Society for Heart and Lung Transplantation: Twenty-second Official Adult Lung and Heart-Lung Transplant Report—2005

Number of centers reporting lung and heart-lung transplantations to the ISHLT Registry by year.

Number of lung transplantations reported by year and procedure type.

Distribution of lung transplantations by center volume, January 1998 to June 2004.

Age distribution of recipients by era.

Indications for adult lung transplantations by year. IPF, idiopathic pulmonary fibrosis; A1A, α₁-anti-trypsin deficiency emphysema; PPH, primary pulmonary hypertension.

Transplantation procedures, by indication and year. AT Def, α₁-anti-trypsin deficiency emphysema; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; PPH, primary pulmonary hypertension.

Induction immunosuppression by year in adult lung recipients for follow-up between January 2000 and December 2003. ALG, anti-lymphocyte globulin; ATG, anti-thymocyte globulin; IL-2R, interleukin-2 receptor.

Percentage of recipients treated for rejection in the first year for transplantations performed from January 2000 through June 2003, stratified by type of induction therapy.

Average number of rejection episodes per recipient in the first year for transplantations performed from January 2000 through June 2003, stratified by type of induction therapy.

Percentage of recipients treated for rejection in the first year for transplantations performed from January 2000 through June 2003, stratified by maintenance immunosuppression regimen. CyA, cyclosporine; TAC, tacrolimus; MMF, mycophenolate mofetil; AZA, azathioprine.

Average number of rejection episodes per recipient in the first year for transplantations performed from January 2000 through June 2003, stratified by maintenance immunosuppressive regimen. CyA, cyclosporine; TAC, tacrolimus; MMF, mycophenolate mofetil; AZA, azathioprine.

Kaplan-Meier survival by procedure type for adult lung transplantations performed between January 1994 and June 2003. Conditional half-life is the time to 50% survival for the sub-set of recipients who were alive at 1 year after transplantation.

Kaplan-Meier survival by era for adult lung transplantations performed between January 1988 and June 2003. Conditional half-life is the time to 50% survival for the sub-set of recipients who were alive at 1 year after transplantation.

Kaplan-Meier survival by age group for adult lung transplantations performed between January 1990 and June 2003.

Kaplan-Meier survival by diagnosis for adult lung transplantations performed between January 1994 and June 2003. Alpha-1, α₁-anti-trypsin deficiency emphysema; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; PPH, primary pulmonary hypertension; CF, cystic fibrosis.

One-year conditional survival by diagnosis for adult lung transplantations performed between January 1994 and June 2003. Alpha-1, α₁-anti-trypsin deficiency emphysema; COPD, chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; PPH, primary pulmonary hypertension; CF, cystic fibrosis.

Kaplan-Meier survival by donor-recipient cytomegalovirus serologic status for adult lung transplantations performed between October 1999 and June 2003. D, donor; R, recipient.

Impact of donor and recipient age on the relative risk of death within 1 year after transplantation for adult lung transplantations performed between January 1995 and June 2003.

Impact of recipient body mass index (BMI) on the relative risk of death within 1 year after transplantation for adult lung transplants performed between January 1995 and June 2003.

Impact of donor weight on the relative risk of death within 1 year after transplantation for adult lung transplants performed between January 1995 and June 2003.

Impact of center volume on the relative risk of death within 1 year after transplantation for adult lung transplantations performed between January 1995 and June 2003.

Freedom from bronchiolitis obliterans syndrome in adult lung recipients for follow-up between April 1994 and June 2004.

Survival models for a 50-year-old man with chronic obstructive pulmonary disease undergoing primary bilateral lung transplantation with or without ventilator support at the time of transplantation. Assumptions for the models: recipient without prior thoracotomy; without inotropic support and without a history malignancy; recipient not hospitalized in the “no ventilator” scenario; 35-year-old cadaveric, ABO-identical organ donor without diabetes mellitus and without clinical evidence of infection; and 3 HLA mismatches but no CMV serology mismatch between donor and recipient.

Number of heart-lung transplantations reported by year.

Indications for heart-lung transplantations by year. COPD, chronic obstructive pulmonary disease; alpha-1, α₁-anti-trypsin deficiency emphysema.

Induction immunosuppression by year in adult heart-lung recipients for follow-up between January 2000 and December 2003. ALG, anti-lymphocyte globulin; ATG, anti-thymocyte globulin; IL-2R, interleukin-2 receptor.

Maintenance immunosuppression drug combinations at 1 year and 5 years after transplantation in adult heart-lung recipients for follow-up between January 2001 and June 2004. Different recipients are analyzed at 1 and 5 years. MMF, mycophenolate mofetil; AZA, azathioprine.

Kaplan-Meier survival for adult heart-lung transplantations performed between January 1982 and June 2003. Conditional half-life is the time to 50% survival for the sub-set of recipients who were alive at 1 year after transplantation.

Kaplan-Meier survival by diagnosis for adult heart-lung transplantations performed between January 1990 and June 2003.

Freedom from coronary artery vasculopathy and bronchiolitis obliterans syndrome in adult heart-lung recipients for follow-up between April 1994 and June 2004. CAV, coronary artery vasculopathy; BOS, bronchiolitis obliterans syndrome.